PET/CT with Gluc-Lys-([18F]FP)-TOCA: Correlation between uptake, size and arterial perfusion in somatostatin receptor positive lesions

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 2, 2008, Pages 264-271

  Wieder, Hinrich ^a   Beer, Ambros J ^a   Poethko, Thorsten ^a   Meisetschlaeger, Guenther ^a   Wester, Hans Juergen ^a   Rummeny, Ernst ^a   Schwaiger, Markus ^a   Stahl, Alexander R ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Neuroendocrine carcinoma; Partial volume effect; Peptide receptor; Radionuclide therapy; Somatostatin receptor

Indexed keywords

N ALPHA (1 DEOXY D FRUCTOSYL) N EPSILON (2 [18F]FLUOROPROPIONYL) LYSINE TYROSINE OCTREOTATE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERY PERFUSION; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DRUG UPTAKE; FEMALE; GLYCOSYLATION; HUMAN; MALE; MORPHOLOGY; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; TUMOR VOLUME;

AGED; ARTERIES; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PEPTIDES, CYCLIC; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 38349147033     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0576-1     Document Type: Article

References (15)

1. Meisetschlager G, Poethko T, Stahl A, Wolf I, Scheidhauer K, Schottelius M, et al. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. J Nucl Med 2006;47:566-73.
2. Schottelius M, Poethko T, Herz M, Reubi JC, Kessler H, Schwaiger M, et al. First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin Cancer Res 2004;10:3593-606.
3. Wester HJ, Schottelius M, Scheidhauer K, Meisetschlager G, Herz M, Rau FC, et al. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel (18)F-labelled, carbohydrated analogue of octreotide. Eur J Nucl Med Mol Imaging 2003;30:117-22.
4. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-82.
5. Stahl A, Meisetschlager G, Schottelius M, Bruus-Jensen K, Wolf I, Scheidhauer K, et al. [(123)I]Mtr-TOCA, a radioiodinated and carbohydrated analogue of octreotide: scintigraphic comparison with [(111)In]octreotide. Eur J Nucl Med Mol Imaging 2006;33:45-52.
6. Wester HJ, Schottelius M, Scheidhauer K, Reubi JC, Wolf I, Schwaiger M. Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics. Eur J Nucl Med Mol Imaging 2002;29:28-38.
7. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34:982-93.
8. Koenig JA, Kaur R, Dodgeon I, Edwardson JM, Humphrey PP. Fates of endocytosed somatostatin sst2 receptors and associated agonists. Biochem J 1998;336 (Pt 2):291-98.
9. Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003;30:207-16.
10. Cremonesi M, Ferrari M, Zoboli S, Chinol M, Stabin MG, Orsi F, et al. Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)- octreotide: implications for internal radiotherapy with (90)Y-DOTATOC. Eur J Nucl Med 1999;26:877-86.
11. Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M. Peptide receptor radionuclide therapy. Ann N Y Acad Sci 2004;1014:234-45.
12. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001;12:941-45.
13. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002;43:610-6.
14. Cremonesi M, Ferrari M, Chinol M, Bartolomei M, Stabin MG, Sacco E, et al. Dosimetry in radionuclide therapies with 90Y-conjugates: the IEO experience. Q J Nucl Med 2000;44:325-32.
15. Brix G, Bellemann ME, Hauser H, Doll J. [Recovery coefficients for the quantification of the arterial input functions from dynamic PET measurements: experimental and theoretical determination]. Nuklearmedizin 2002;41:184-90.